Amgen Inc (AMGN · NASDAQ)
AMGN · MARKET VIEW
Market view · as of Jun 15, 2026
Revenue (TTM)
$37.22B
+5.8% YoY
Gross margin
71.4%
EPS (latest q)
$5.15
vs $4.77 est · beat
52-wk position
75.2%
-7.8% vs 52w high · +6.5% 1mo
Price (last ~year)
Amgen Inc. (AMGN) shares are trading at $355.20, slightly above the $352.50 average analyst price target, amid a landscape of recent patent litigation and mixed analyst revisions. The company reported $37.22 billion in trailing twelve-month revenue with 5.8% year-over-year growth, supported by a 21.0% profit margin and $1.48 billion in free cash flow for the quarter ending March 31, 2026.
Valuation
- Market cap
- $191.70B
- P/E
- 24.68
- PEG
- 2.348
- P/B
- 20.86
- P/S
- 5.15
- EV/EBITDA
- 14.21
- Beta
- 0.416
- Analyst target
- $352.5
Quality & returns
- Gross margin
- 71.4%
- Operating margin
- 33.8%
- Profit margin
- 21.0%
- ROE
- 101.3%
- ROA
- 8.3%
Price movement
- Last
- $355.20
- 1-month
- +6.5%
- 3-month
- +1.8%
- RSI (14)
- 63
- vs SMA200
- +8.8%
- 52-wk position
- 75.2% -7.8% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-03-31 | $8.62B | $2.67B | $1.82B | $3.86B |
| 2025-12-31 | $9.90B | $3.94B | $1.33B | $3.30B |
| 2025-09-30 | $9.56B | $2.53B | $3.22B | $5.91B |
| 2025-06-30 | $9.17B | $2.64B | $1.43B | $3.62B |
Recent news
- Bearish Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape · 2026-06-14
- Neutral Healthcare of Ontario Pension Plan Trust Fund Sells 64,867 Shares of Amgen Inc. $AMGN · 2026-06-14
- Neutral Atlas Capital Advisors Inc. Takes $2.20 Million Position in Amgen Inc. $AMGN · 2026-06-14
- Somewhat-Bullish Amgen (AMGN) Stock Valuation Looks Split Between Analyst Targets And DCF Upside · 2026-06-14
- Somewhat-Bullish Morgan Stanley Raises Amgen (AMGN) Price Target Following a Strong Start for Uplizna · 2026-06-14
- Somewhat-Bullish Wall Street Zen Upgrades Amgen (NASDAQ:AMGN) to Buy · 2026-06-14
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)